Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Clinical trial NCT03095274 · COMPLETED
Trial details
- NCT number
- NCT03095274
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-11
- Primary completion
- 2019-11-30
- Enrollment
- 126
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.